Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Both“
Suchtreffer
Begriffe & Kennungen
Clopidogrel BGR (previously Zylagren) · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnenClopidogrel HCS · 4.8 · 7 In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both g
Eintrag öffnenClopidogrel HCS · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Krka d.d. (previously Zopya) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Krka d.d. (previously Zopya) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Krka d.d. (previously Zopya) · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnenClopidogrel Krka · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Krka · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Krka · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnenClopidogrel TAD · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel TAD · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel TAD · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.8 · In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both gro
Eintrag öffnenClopidogrel Teva (hydrogen sulphate) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Teva (hydrogen sulphate) · 4.8 · 9 In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both g
Eintrag öffnenClopidogrel Teva (hydrogen sulphate) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · 9 In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both g
Eintrag öffnen